VolitionRx Announces Q3 2026 Financial Results and Nu.Q Platform Progress
VolitionRx Limited (VNRX) has reported its third-quarter 2026 financial results, highlighting significant operational progress across its Nu.Q® platform pillars. The company is advancing clinical utility for sepsis detection through the DETECSEPS program in France and has demonstrated prognostic value for mortality in recent publications. To expand global reach, VolitionRx signed a Letter of Intent with Missionpharma to target neonatal sepsis in resource-constrained settings. In its oncology segment, the company is preparing a French reimbursement submission for Nu.Q® Lung Cancer and is engaged in licensing discussions for its Capture-Seq™ technology within the multi-billion dollar liquid biopsy market. Additionally, VolitionRx reported progress in its veterinary division with high specificity results for feline lymphoma detection. Management also noted efforts to strengthen the balance sheet through cost reductions and debt reduction.
Topics: business update clinical data debt reduction financial results sepsis detection